Posted in Regulatory FDA delays decision on Sanofi’s subcutaneous Sarclisa April 22, 2026 Pharmaphorum The FDA has extended its review of a new version of Sanofi’s multiple myeloma Sarclisa that could help narrow the gap with arch-rival Darzalex. RegulatoryOncologyRead full story